Yuan Xu

8PUBLICATIONS
18CO-AUTHORS
Applied immunology (incl. antibody engineering, xenotransplantation and t-cell therapies)Gene and molecular therapyCancer therapy (excl. chemotherapy and radiation therapy)NeonatologyChemotherapy
Featured researcher

Get your video featured.

JoVEPublish with JoVE
Journal

Publications (8)

|Jun 05, 2026
The Effect of Efavirenz and Rufinamide on the Pharmacokinetics and Safety of Quizartinib: Two Phase 1 Studies in Healthy Participants.

|May 23, 2025
Integrated Two-Analyte Population Pharmacokinetics Model of Patritumab Deruxtecan (HER3-DXd) Monotherapy in Patients with Solid Tumors.

Yuan Xu, Mark Lee, Rujuta Joshi

|Apr 11, 2025
Exposure-Response Relationships in Patients with Non-Small-Cell Lung Cancer and Other Solid Tumors Treated with Patritumab Deruxtecan (HER3-DXd).

Li Li, Mark Lee, Rujuta Joshi

|Mar 08, 2022
FDA Approval Summary: Ivosidenib for the Treatment of Patients with Advanced Unresectable or Metastatic, Chemotherapy Refractory Cholangiocarcinoma with an IDH1 Mutation.

Sandra J Casak, Shan Pradhan, Lola A Fashoyin-Aje

|Feb 01, 2022
FDA Approval Summary: Pembrolizumab, Atezolizumab, and Cemiplimab-rwlc as Single Agents for First-Line Treatment of Advanced/Metastatic PD-L1-High NSCLC.

Oladimeji Akinboro, Erin Larkins, Lee H Pai-Scherf

|Mar 13, 2021
FDA Approval Summary: Selumetinib for Plexiform Neurofibroma.

Denise Casey, Suzanne Demko, Arup Sinha

Pageof 2

Frequent Collaborators

2 joint publications

Martha Donoghue

2 joint publications

Lola Fashoyin-Aje

2 joint publications

Kirsten B Goldberg

1 joint publications

Jian Wang